Overview

Study of SHR-A1811 in HER2-positive Advanced Breast Cancer With Brain Metastases

Status:
Not yet recruiting
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
This study aimed to evaluate the use of SHR-A1811 in HER2-positive Advanced Breast Cancer patients with brain metastases.
Phase:
Phase 2
Details
Lead Sponsor:
Henan Cancer Hospital
Treatments:
Bevacizumab